Michael Krams

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi request reprint ASTIN: a Bayesian adaptive dose-response trial in acute stroke
    Andrew P Grieve
    Statistical Research and Consulting Centre, Pfizer Global Research and Development, Sandwich, Kent, UK
    Clin Trials 2:340-51; discussion 352-8, 364-78. 2005
  2. ncbi request reprint Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke
    Michael Krams
    Pfizer Global Research and Development, Sandwich, UK
    Stroke 34:2543-8. 2003
  3. ncbi request reprint Role of mechanistically-based pharmacokinetic/pharmacodynamic models in drug development : a case study of a therapeutic protein
    Scott Marshall
    Department of Clinical Pharmacology, Pfizer Global Research and Development, Sandwich, UK
    Clin Pharmacokinet 45:177-97. 2006
  4. ncbi request reprint UK-279,276, a neutrophil inhibitory glycoprotein, in acute stroke: tolerability and pharmacokinetics
    Kennedy R Lees
    University Department of Medicine and Therapeutics, Gardiner Institute, Western Infirmary, Glasgow, G11 6NT, UK
    Stroke 34:1704-9. 2003
  5. ncbi request reprint A longitudinal model for non-monotonic clinical assessment scale data
    Fredrik Jonsson
    Department of Pharmaceutical Biosciences Division of Pharmacokinetics and Drug Therapy, Uppsala University, Sweden
    J Pharmacokinet Pharmacodyn 32:795-815. 2005
  6. ncbi request reprint Bridging the pharmacokinetics and pharmacodynamics of UK-279,276 across healthy volunteers and stroke patients using a mechanistically based model for target-mediated disposition
    E Niclas Jonsson
    Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, Box 591, SE 751 24, Uppsala, Sweden
    Pharm Res 22:1236-46. 2005
  7. ncbi request reprint Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke
    Li Zhang
    Department of Neurology, Henry Ford Health Sciences Center, Detroit, MI 48202, USA
    Stroke 34:1790-5. 2003
  8. ncbi request reprint Assessing combination treatments in acute stroke: preclinical experiences
    Mei Lu
    Department of Biostatistics and Research Epidemiology, Henry Ford Health Sciences Center, One Ford Place 3E, Detroit, MI 48202, USA
    Behav Brain Res 162:165-72. 2005
  9. ncbi request reprint The past is the future: innovative designs in acute stroke therapy trials
    Michael Krams
    Pfizer Global Research and Development, Groton, Conn, USA
    Stroke 36:1341-7. 2005
  10. ncbi request reprint Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke
    Giora Z Feuerstein
    Wyeth Research, Collegeville, Pennsylvania 19426, USA
    J Cereb Blood Flow Metab 28:217-9. 2008

Collaborators

Detail Information

Publications10

  1. ncbi request reprint ASTIN: a Bayesian adaptive dose-response trial in acute stroke
    Andrew P Grieve
    Statistical Research and Consulting Centre, Pfizer Global Research and Development, Sandwich, Kent, UK
    Clin Trials 2:340-51; discussion 352-8, 364-78. 2005
    ..The design was deployed in ASTIN, a phase II proof-of-concept trial of the neuroprotectant, neutrophil inhibitory factor (NIF), in acute stroke. We discuss the learning from this trial...
  2. ncbi request reprint Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke
    Michael Krams
    Pfizer Global Research and Development, Sandwich, UK
    Stroke 34:2543-8. 2003
    ..The prime objective was to determine the dose that gave a clinically relevant effect in patients...
  3. ncbi request reprint Role of mechanistically-based pharmacokinetic/pharmacodynamic models in drug development : a case study of a therapeutic protein
    Scott Marshall
    Department of Clinical Pharmacology, Pfizer Global Research and Development, Sandwich, UK
    Clin Pharmacokinet 45:177-97. 2006
    ..UK-279,276 binds to the CD11b/CD18 (MAC-1) on neutrophils and was under development for the treatment of ischaemic stroke...
  4. ncbi request reprint UK-279,276, a neutrophil inhibitory glycoprotein, in acute stroke: tolerability and pharmacokinetics
    Kennedy R Lees
    University Department of Medicine and Therapeutics, Gardiner Institute, Western Infirmary, Glasgow, G11 6NT, UK
    Stroke 34:1704-9. 2003
    ..The purposes of this study were to evaluate the safety and tolerability of UK-279,276 and to examine its pharmacokinetics and pharmacodynamics (binding to neutrophil CD11b) in patients with acute stroke...
  5. ncbi request reprint A longitudinal model for non-monotonic clinical assessment scale data
    Fredrik Jonsson
    Department of Pharmaceutical Biosciences Division of Pharmacokinetics and Drug Therapy, Uppsala University, Sweden
    J Pharmacokinet Pharmacodyn 32:795-815. 2005
    ..We conclude that this approach has considerable potential for more efficient use of information in longitudinal modeling of non-monotonic clinical assessment scale data...
  6. ncbi request reprint Bridging the pharmacokinetics and pharmacodynamics of UK-279,276 across healthy volunteers and stroke patients using a mechanistically based model for target-mediated disposition
    E Niclas Jonsson
    Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, Box 591, SE 751 24, Uppsala, Sweden
    Pharm Res 22:1236-46. 2005
    ..The aim of this current analysis was to develop a mechanistically based model to bridge the differences between healthy volunteers and patients...
  7. ncbi request reprint Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke
    Li Zhang
    Department of Neurology, Henry Ford Health Sciences Center, Detroit, MI 48202, USA
    Stroke 34:1790-5. 2003
    ..We evaluated the neuroprotective effect of UK-279,276 (also referred to as recombinant neutrophil inhibitory factor), a selective CD11b/CD18 antagonist, in combination with thrombolytic therapy on focal cerebral ischemia...
  8. ncbi request reprint Assessing combination treatments in acute stroke: preclinical experiences
    Mei Lu
    Department of Biostatistics and Research Epidemiology, Henry Ford Health Sciences Center, One Ford Place 3E, Detroit, MI 48202, USA
    Behav Brain Res 162:165-72. 2005
    ..Treatment success may require combining different therapeutic approaches. An obvious treatment combination in acute ischemic stroke is a thrombolytic therapy, adjuvant with a neuroprotective agent to have better stroke recovery...
  9. ncbi request reprint The past is the future: innovative designs in acute stroke therapy trials
    Michael Krams
    Pfizer Global Research and Development, Groton, Conn, USA
    Stroke 36:1341-7. 2005
  10. ncbi request reprint Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke
    Giora Z Feuerstein
    Wyeth Research, Collegeville, Pennsylvania 19426, USA
    J Cereb Blood Flow Metab 28:217-9. 2008
    ..Finally, rational patient selection and new outcome scales tailored in an adaptive design model must be evaluated...